Impact of surgery after endoscopically resected high-risk T1 colorectal cancer: results of an emulated target trial

Gastrointest Endosc. 2024 Mar;99(3):408-416.e2. doi: 10.1016/j.gie.2023.09.027. Epub 2023 Oct 2.

Abstract

Background and aims: We aimed to compare the long-term outcomes of patients with high-risk T1 colorectal cancer (CRC) resected endoscopically who received either additional surgery or surveillance.

Methods: We used data from routine care to emulate a target trial aimed at comparing 2 strategies after endoscopic resection of high-risk T1 CRC: surgery with lymph node dissection (treatment group) versus surveillance alone (control group). All patients from 14 tertiary centers who underwent an endoscopic resection for high-risk T1 CRC between March 2012 and August 2019 were included. The primary outcome was a composite outcome of cancer recurrence or death at 48 months.

Results: Of 197 patients included in the analysis, 107 were categorized in the treatment group and 90 were categorized in the control group. From baseline to 48 months, 4 of 107 patients (3.7%) died in the treatment group and 6 of 90 patients (6.7%) died in the control group. Four of 107 patients (3.7%) in the treatment group experienced a cancer recurrence and 4 of 90 patients (4.4%) in the control group experienced a cancer recurrence. After balancing the baseline covariates by inverse probability of treatment weighting, we found no significant difference in the rate of death and cancer recurrence between patients in the 2 groups (weighted hazard ratio, .95; 95% confidence interval, .52-1.75).

Conclusions: Our study suggests that patients with high-risk T1 CRC initially treated with endoscopic resection may not benefit from additional surgery.

MeSH terms

  • Colorectal Neoplasms* / pathology
  • Colorectal Neoplasms* / surgery
  • Endoscopy / methods
  • Humans
  • Lymph Node Excision
  • Neoplasm Recurrence, Local* / pathology
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome